Some day no one will believe cancer surgery was once performed without Tumor Paint Technology.
Blaze Bioscience, Inc. is a privately held biotechnology company focused on guided therapies. Blaze was founded in 2010 by Dr. Jim Olson, a pediatric neuro-oncologist at the Fred Hutchinson Cancer Research Center and Seattle Children’s Hospital, and Heather Franklin, a former senior business executive from ZymoGenetics. Blaze is working to develop Tumor Paint products and Optide*-based guided therapeutics.
Surgery is first line therapy for most solid tumor cancers and Tumor Paint products intend to improve cancer surgery by providing real-time, high-resolution visualization of cancer cells throughout surgery. The ability to see cancer cells in real time and high resolution throughout surgery should enable better detection as well as more precise and complete surgical removal of cancer—while sparing surrounding normal tissue. The first Tumor Paint product candidate, BLZ-100, is in Phase 1 clinical trials for brain and breast cancers. Additional potential applications of BLZ-100 include prostate, lung, colorectal and other solid tumor cancers.
Blaze has an ongoing collaboration with the Fred Hutchinson Cancer Research Center focused on the discovery and development of Optide-based products for use as guided therapeutics.
* Optides, or “optimized peptides,” are tiny molecules originally derived from natural organisms, such as scorpions, violets and sunflowers and optimized for drug-like properties in the research laboratory.